Genotoxicity evaluation of individual cigarette smoke toxicants using the in vitro γH2AX assay by High Content Screening

Toxicology Letters

Volumn 223, Issue 1, 2013, Pages 81-87

  Garcia Canton, Carolina ^a,b   Anadon, Arturo ^b   Meredith, Clive ^a  

^a BRITISH AMERICAN TOBACCO   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

H2AX; Cigarette smoke; Genotoxicity; In vitro; Tobacco regulation

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; BENZO[A]PYRENE; CADMIUM CHLORIDE; CIGARETTE SMOKE; GAMMAH2AX PROTEIN; HISTONE H2AX; NITROSONORNICOTINE; TOBACCO SMOKE; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; FLUORESCENCE MICROSCOPY; GENOTOXICITY; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL; PROTEIN DETERMINATION;

CIGARETTE SMOKE; GENOTOXICITY; IN VITRO; TOBACCO REGULATION; ΓH2AX;

BENZO(A)PYRENE; BRONCHI; CADMIUM; CELL LINE; EPITHELIAL CELLS; HISTONES; HUMANS; MUTAGENICITY TESTS; NITROSAMINES; SMOKE; TOBACCO;

EID: 84884584271     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.08.024     Document Type: Article

References (50)

1. Alexandrov K., Rojas M., Satarug S. The critical DNA damage by benzo(a)pyrene in lung tissues of smokers and approaches to preventing its formation. Toxicol. Lett. 2010, 198:63-68.
2. Antherieu S., Chesne C., Li R.Y., Camus S., Lahoz A., Picazo L., Turpeinen M., Tolonen A., Uusitalo J., Guguen-Guillouzo C., Guillouzo A. Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells. Drug Metab. Dispos. 2010, 38:516-525.
3. Audebert M., Riu A., Jacques C., Hillenweck A., Jamin E.L., Zalko D., Cravedi J.P. Use of the gammaH2AX assay for assessing the genotoxicity of polycyclic aromatic hydrocarbons in human cell lines. Toxicol. Lett. 2010, 199:182-192.
4. Brandon E.F., Raap C.D., Meijerman I., Beijnen J.H., Schellens J.H. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol. Appl. Pharmacol. 2003, 189:233-246.
5. Burns D.M., Dybing E., Gray N., Hecht S., Anderson C., Sanner T., O'Connor R., Djordjevic M., Dresler C., Hainaut P., Jarvis M., Opperhuizen A., Straif K. Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal. Tob. Control 2008, 17:132-141.
6. Cunningham F.H., Fiebelkorn S., Johnson M., Meredith C. A novel application of the margin of exposure approach: segregation of tobacco smoke toxicants. Food Chem. Toxicol. 2011, 49:2921-2933.
7. Darzynkiewicz Z., Zhao H., Halicka H.D., Rybak P., Dobrucki J., Wlodkowic D. DNA damage signaling assessed in individual cells in relation to the cell cycle phase and induction of apoptosis. Crit. Rev. Clin. Lab. Sci. 2012, 49:199-217.
8. Easterbrook J., Fackett D., Li A.P. A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and testosterone 6beta-hydroxylation. Chem. Biol. Interact. 2001, 134:243-249.
9. FDA Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List 2012, http://www.fda.gov/TobaccoProducts/GuidanceComplianceRegulatoryInformation/ucm297786.htm# (accessed June 2013).
10. FDA Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act 2012, http://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297828.pdf.
11. Forti E., Bulgheroni A., Cetin Y., Hartung T., Jennings P., Pfaller W., Prieto P. Characterisation of cadmium chloride induced molecular and functional alterations in airway epithelial cells. Cell Physiol. Biochem. 2010, 25:159-168.
12. Fowler P., Whitwell J., Jeffrey L., Young J., Smith K., Kirkland D. Cadmium chloride, benzo[a]pyrene and cyclophosphamide tested in the in vitro mammalian cell micronucleus test (MNvit) in the human lymphoblastoid cell line TK6 at Covance laboratories, Harrogate UK in support of OECD draft Test Guideline 487. Mutat. Res. 2010, 702:171-174.
13. Fowles J., Dybing E. Application of toxicological risk assessment principles to the chemical constituents of cigarette smoke. Tob. Control 2003, 12:424-430.
14. Garcia-Canton C., Anadon A., Meredith C. gammaH2AX as a novel endpoint to detect DNA damage: Applications for the assessment of the in vitro genotoxicity of cigarette smoke. Toxicol. In Vitro 2012, 26:1075-1086.
15. Garcia-Canton C., Minet E., Anadon A., Meredith C. Metabolic characterization of cell systems used in in vitro toxicology testing: lung cell system BEAS-2B as a working example. Toxicol. In Vitro 2013, 27:1719-1727.
16. Garcia-Canton C., Anadon A., Meredith C. Assessment of the in vitro γH2AX assay by High Content Screening as a novel genotoxicity test. Mutat. Res. 2013, (in press). 10.1016/j.mrgentox.2013.08.002.
17. Grosse Y., Monje M.C., Mace K., Pfeifer A.M., Pfohl-leszkowicz A. Use of bronchial epithelial cells expressing human cytochrome P450 for study on metabolism and genotoxicity of ochratoxin A. In Vitro Toxicol. 1997, 10:93-102.
18. Hartwig A. Mechanisms in cadmium-induced carcinogenicity: recent insights. Biometals 2010, 23:951-960.
19. Hecht S.S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res. 1999, 424:127-142.
20. Hecht S.S., Tricker A.R. Nitrosamines derived from nicotine and other tobacco alkaloids. Analytical Determination of Nicotine and Related Compounds and their Metabolites 1999, 421-488. Elsevier Science, Amsterdam, (Chapter 11). W.G. John, I.I.I. Peyton Jacob (Eds.).
21. IARC, 2012a. IARC monographs on the evaluation of carcinogenic risk to humans. A review of human carcinogens: chemical agents and related occupations. Benzo[a]pyrene. 100F.
22. IARC, 2012b. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens: personal habits and indoor combustions. N'-Nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). International Agency for Research on Cancer. 100E.
23. IARC, 2012c. IARC monographs on the evaluation of carcinogenic risk to humans. A review of human carcinogens: carcinogenic metals, arsenic, fibres and dust. Cadmium and Cadmium Compounds. 100C.
24. IARC TP53 Database 2013, http://p53.iarc.fr/ (accessed June 2013).
25. ICH, 2011. Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use S2(R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S2_R1/Step4/S2R1_Step4.pdf.
26. Johnson M.D., Schilz J., Djordjevic M.V., Rice J.R., Shields P.G. Evaluation of in vitro assays for assessing the toxicity of cigarette smoke and smokeless tobacco. Cancer Epidemiol. Biomarkers Prev. 2009, 18:3263-3304.
27. Kirkland D., Pfuhler S., Tweats D., Aardema M., Corvi R., Darroudi F., Elhajouji A., Glatt H., Hastwell P., Hayashi M., Kasper P., Kirchner S., Lynch A., Marzin D., Maurici D., Meunier J.R., Muller L., Nohynek G., Parry J., Parry E., Thybaud V., Tice R., van Benthem J., Vanparys P., White P. How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: report of an ECVAM workshop. Mutat. Res. 2007, 628:31-55.
28. Liu L.L., Alaoui-Jamali M.A., el A.N., Castonguay A. Metabolism and DNA single strand breaks induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its analogues in primary culture of rat hepatocytes. Cancer Res. 1990, 50:1810-1816.
29. Lugon-Moulin N., Martin F., Krauss M.R., Ramey P.B., Rossi L. Cadmium concentration in tobacco (Nicotiana tabacum L.) from different countries and its relationship with other elements. Chemosphere 2006, 63:1074-1086.
30. Lynch A.M., Parry J.M. The cytochalasin-B micronucleus/kinetochore assay in vitro: studies with 10 suspected aneugens. Mutat. Res. 1993, 287:71-86.
31. Lynch A.M., Sasaki J.C., Elespuru R., Jacobson-Kram D., Thybaud V., De Boeck M., Aardema M.J., Aubrecht J., Benz R., Dertinger S.D., Douglas G.R., White P.A., Escobar P.A., Fornace A., Honma M., Naven R.T., Rusling J.F., Schiestl R.H., Walmsley R.M., Yamamura E., van Benthem J., Kim J.H. New and emerging technologies for genetic toxicity testing. Environ. Mol. Mutagen. 2011, 52:205-223.
32. Mace K., Offord E.A., Pfeifer A.M.A. Drug metabolism and carcinogen activation studies with human genetically engineered cells. In Vitro Methods in Pharmaceutical Research 1997, 433-456. Academic Press, London. J.V. Castell, M.J. Gomez-Lechon (Eds.).
33. Mukherjee B., Kessinger C., Kobayashi J., Chen B.P., Chen D.J., Chatterjee A., Burma S. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells. DNA Repair (Amst.) 2006, 5:575-590.
34. Nims R.W., Sykes G., Cottrill K., Ikonomi P., Elmore E. Short tandem repeat profiling: part of an overall strategy for reducing the frequency of cell misidentification. In Vitro Cell Dev. Biol. Anim. 2010, 46:811-819.
35. Perfetti T.A., Rodgman A. The complexity of tobacco and tobacco smoke. Contrib. Tob. Res. 2011, 24:215-232.
36. Peterson L.A., Spratt T.E., Shan W., Wang L., Subotkowski W., Roth R. An improved synthesis of radiolabeled 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone. J. Label. Comp. Radiopharm. 2001, 44:445-450.
37. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
38. Reddel R.R., Ke Y., Gerwin B.I., McMenamin M.G., Lechner J.F., Su R.T., Brash D.E., Park J.B., Rhim J.S., Harris C.C. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res. 1988, 48:1904-1909.
39. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 1998, 273:5858-5868.
40. Schechtman L.M. Implementation of the 3Rs (refinement, reduction, and replacement): validation and regulatory acceptance considerations for alternative toxicological test methods. ILAR J. 2002, 43(Suppl.):S85-S94.
41. Seoane A.I., Dulout F.N. Genotoxic ability of cadmium, chromium and nickel salts studied by kinetochore staining in the cytokinesis-blocked micronucleus assay. Mutat. Res. 2001, 490:99-106.
42. Smart D.J., Ahmedi K.P., Harvey J.S., Lynch A.M. Genotoxicity screening via the gammaH2AX by flow assay. Mutat. Res. 2011, 715:25-31.
43. Su T., Bao Z., Zhang Q.Y., Smith T.J., Hong J.Y., Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. 2000, 60:5074-5079.
44. Svetlova M.P., Solovjeva L.V., Tomilin N.V. Mechanism of elimination of phosphorylated histone H2AX from chromatin after repair of DNA double-strand breaks. Mutat. Res. 2010, 685:54-60.
45. Taylor D.L. A personal perspective on high-content screening (HCS): from the beginning. J. Biomol. Screen. 2010, 15:720-725.
46. Waisberg M., Joseph P., Hale B., Beyersmann D. Molecular and cellular mechanisms of cadmium carcinogenesis. Toxicology 2003, 192:95-117.
47. Watanabe T., Shimada T., Endo A. Mutagenic effects of cadmium on mammalian oocyte chromosomes. Mutat. Res. 1979, 67:349-356.
48. Watters G.P., Smart D.J., Harvey J.S., Austin C.A. H2AX phosphorylation as a genotoxicity endpoint. Mutat. Res. 2009, 679:50-58.
49. WHO, 2008. The Scientific Basis of Tobacco Product Regulation. WHO Technical Report Series, no. 951. http://www.who.int/tobacco/global_interaction/tobreg/publications/9789241209519.pdf.
50. Zhang X., D'Agostino J., Wu H., Zhang Q.Y., von W.L., Murphy S.E., Ding X. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. J. Pharmacol. Exp. Ther. 2007, 323:570-578.